Literature DB >> 33987818

In Vitro and In Vivo Cholesterol Reducing Ability and Safety of Probiotic Candidates Isolated from Korean Fermented Soya Beans.

Eric Banan-Mwine Daliri1, Yeju Kim1, Yujeong Do1, Ramachandran Chelliah1, Deog-Hwan Oh2.   

Abstract

Hypercholesterolemia is a risk factor for cardiovascular diseases, and hence, reducing serum cholesterol levels could reduce the incidence. In this study, we ascertained the cholesterol-reducing potential of lactic acid bacteria (LAB) isolated from Korean fermented soybean paste. Live, resting, and dead cells of all the bacteria reduced cholesterol in liquid media in a strain-dependent manner. Live cells of Weissella cibaria SCCB2306, Pediococcus acidilactici SDL1402, P. acidilactici SDL1406, and Lactobacillus rhamnosus JDFM6 reduced the most cholesterol in liquid media by 78 ± 3%, 72 ± 3%, 76 ± 3%, 75 ± 5%, and 79 ± 2%, respectively. As the cholesterol levels in the media reduced, cell membrane lipids of P. acidilactici SDL1402, P. acidilactici SDL1406, and L. rhamnosus JDFM6 increased by 23.36 mg/mL, 6.53 mg/mL, and 8.14 mg/mL, respectively, indicating that cholesterol was incorporated into the bacteria cell membranes. All the bacteria displayed bile salt hydrolase activities in a strain-dependent manner. Though all four LAB significantly reduced cholesterol levels in Caenorhabditis elegans irrespective of the order of feeding, L. rhamnosus JDFM6 reduced the most cholesterol in vivo (up to 40% of ingested cholesterol). None of the four LAB hydrolyzed mucin or gelatin and none was toxic to C. elegans. The concentrations of phenylethylamine, putrescine, cadaverine, histamine, and tyramine produced by the LAB were below the toxic limits of biogenic amines set by the European Food Safety Authority. Taken together, our results demonstrate that Weissella cibaria SCCB2306, P. acidilactici SDL1402, P. acidilactici SDL1405, and L. rhamnosus JDFM6 could be safe cholesterol-reducing probiotic candidates for preventing or managing hypercholesterolemia.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cardiovascular disease; Cholesterol-reducing probiotics; Hypercholesterolemia; Non-pharmacological therapeutics; Safety

Mesh:

Substances:

Year:  2021        PMID: 33987818     DOI: 10.1007/s12602-021-09798-0

Source DB:  PubMed          Journal:  Probiotics Antimicrob Proteins        ISSN: 1867-1306            Impact factor:   4.609


  23 in total

1.  Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults.

Authors:  Mitchell L Jones; Christopher J Martoni; Mathieu Parent; Satya Prakash
Journal:  Br J Nutr       Date:  2011-11-09       Impact factor: 3.718

Review 2.  The perspective on cholesterol-lowering mechanisms of probiotics.

Authors:  Nestor Ishimwe; Eric B Daliri; Byong H Lee; Fang Fang; Guocheng Du
Journal:  Mol Nutr Food Res       Date:  2015-01       Impact factor: 5.914

3.  Relation of Cardiovascular Events and Deaths to Low-Density Lipoprotein Cholesterol Level Among Statin-Treated Patients With Atherosclerotic Cardiovascular Disease.

Authors:  Alanna M Chamberlain; Sarah S Cohen; Susan A Weston; Kathleen M Fox; Pin Xiang; Jill M Killian; Yi Qian
Journal:  Am J Cardiol       Date:  2019-03-08       Impact factor: 2.778

4.  Cholesterol lowering and inhibition of sterol absorption by Lactobacillus reuteri NCIMB 30242: a randomized controlled trial.

Authors:  M L Jones; C J Martoni; S Prakash
Journal:  Eur J Clin Nutr       Date:  2012-09-19       Impact factor: 4.016

5.  Effect of fermented milk (yogurt) containing Lactobacillus acidophilus L1 on serum cholesterol in hypercholesterolemic humans.

Authors:  J W Anderson; S E Gilliland
Journal:  J Am Coll Nutr       Date:  1999-02       Impact factor: 3.169

6.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.

Authors:  Marc S Sabatine; Robert P Giugliano; Anthony C Keech; Narimon Honarpour; Stephen D Wiviott; Sabina A Murphy; Julia F Kuder; Huei Wang; Thomas Liu; Scott M Wasserman; Peter S Sever; Terje R Pedersen
Journal:  N Engl J Med       Date:  2017-03-17       Impact factor: 91.245

Review 7.  Effectiveness and Safety of Inclisiran, A Novel Long-Acting RNA Therapeutic Inhibitor of Proprotein Convertase Subtilisin/Kexin 9.

Authors:  Gopal Chandra Ghosh; Dhrubajyoti Bandyopadhyay; Raktim K Ghosh; Samhati Mondal; Eyal Herzog
Journal:  Am J Cardiol       Date:  2018-07-03       Impact factor: 2.778

Review 8.  The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials.

Authors:  J J Brugts; T Yetgin; S E Hoeks; A M Gotto; J Shepherd; R G J Westendorp; A J M de Craen; R H Knopp; H Nakamura; P Ridker; R van Domburg; J W Deckers
Journal:  BMJ       Date:  2009-06-30

9.  Reduction of serum cholesterol and its mechanism by Lactobacillus plantarum H6 screened from local fermented food products.

Authors:  Tianming Qu; Liu Yang; Yuhua Wang; Bin Jiang; Minghao Shen; Dayong Ren
Journal:  Food Funct       Date:  2020-02-26       Impact factor: 5.396

10.  Sub-optimal cholesterol response to initiation of statins and future risk of cardiovascular disease.

Authors:  Ralph Kwame Akyea; Joe Kai; Nadeem Qureshi; Barbara Iyen; Stephen F Weng
Journal:  Heart       Date:  2019-04-15       Impact factor: 5.994

View more
  1 in total

Review 1.  Research Update on the Impact of Lactic Acid Bacteria on the Substance Metabolism, Flavor, and Quality Characteristics of Fermented Meat Products.

Authors:  Yi Wang; Jun Han; Daixun Wang; Fang Gao; Kaiping Zhang; Jianjun Tian; Ye Jin
Journal:  Foods       Date:  2022-07-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.